Analysis of 136 reports of adverse reactions related to small molecule kinase inhibitors

doi:10.19803/j.1672-8629.20230148

Abstract

Abstract: Objective To analyze the characteristics of adverse drug reactions (ADR) of small molecule kinase inhibitors (SMKI), and provide reference for rational use of drugs in clinic. Methods The data on 136 cases of SMKI-related ADR monitored in our hospital between 2011 and 2022 was analyzed while the characteristics and risks of ADR caused by SMKI were studied in terms of patients, drug use, and occurrence of ADR. Results One hundred and thirty-six cases of ADR involved 21 types of SMKI. The average age of the patients was 57.75±12.74, and patients with lung cancer accounted for 54.41%. There were 34 cases of off-label use of drugs. The systems-organs implicated in ADR were mainly the gastrointestinal system, followed by the skin and subcutaneous tissue. 54.41% of the patients with ADR did not have the dosage of SMKI adjusted, 16.91% were severe ADR cases, and 56.62% improved after treatment. Conclusion SMKI-related ADR are tolerable for most of the patients. Some patients require dose reduction and symptomatic treatment. ADR can implicate multiple systems-organs. Patients should be assisted in targeted ADR monitoring and management to improve the safety and compliance of medication.

Key words: small molecule kinase inhibitor, adverse drug reaction, oral targeted drug, lung cancer, gastrointestinal system, skin, subcutaneous tissue, EGFR

CLC Number:

JIA Bei, WANG Weihua, YANG Liang, DAI Yuanyuan. Analysis of 136 reports of adverse reactions related to small molecule kinase inhibitors[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1163-1167.

References

[1] BOURNEZ C, CARLES F, PEYRAT G, et al.Comparative assessment of protein kinase inhibitors in public databases and in PKIDB[J]. Molecules, 2020, 25(14): 3226.
[2] ROSKOSKI R JR.Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update[J]. Pharmacol Res, 2023, 187: 106552.
[3] SMITH P, LAVERY A, TURKINGTON RC. An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management[J]. Best Pract Res Clin Gastroenterol, 2020, 48-49: 101691.
[4] COLEMAN EL, OLAMIJU B, LEVENTHAL JS.Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review)[J]. Oncol Rep, 2021, 45(3): 891-898.
[5] AGARWAL M, THAREJA N, BENJAMIN M, et al.Tyrosine kinase inhibitor-induced hypertension[J]. Curr Oncol Rep, 2018, 20(8): 65.
[6] JIANG H, JIN Y, YAN H, et al.Hepatotoxicity of FDA-approved small molecule kinase inhibitors[J]. Expert Opin Drug Saf, 2021, 20(3): 335-348.
[7] MedDRA. MedDRA Version 25.1[EB/OL]. [2023-01-24]. https://www.meddra.org/how-to-use/support-documentation/english/welcome.
[8] National Medical Products Administration. Measures for the reporting and monitoring of adverse drug reaction(Decree No. 81 of the Ministry of Health) [EB/OL]. (2011-05-04) [2023-01-24]. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110504162501325_7.html.
[9] ZHENG R, ZHANG S, ZENG H, et al.Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022, 2(1): 1-9.
[10] LONG CT, SHAO M, LU XY.Research progress on small molecule kinase inhibitors[J]. Acta Pharmaceutica Sinica(药学学报), 2021, 56(2): 414-431.
[11] ZHAO Y, CHENG B, CHEN Z, et al.Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis[J]. Crit Rev Oncol Hematol, 2021, 160: 103305.
[12] FU Y, WEI X, LIN L, et al.Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors[J]. Thorac Cancer, 2018, 9(5): 542-547.
[13] SKVRCE NM, GALIC I, PACADI C, et al.Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation[J]. Res Social Adm Pharm, 2020, 16(7): 928-934.
[14] The Drug Risk Management Group, Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Expert consensus of off-label drug use[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2015, 17(2): 101-103.
[15] MENG XY, LIANG YH, ATIHENIMU AMT, et al.Analysis of off-label use of 2000 outpatient anti-tumor drug prescriptions[J]. Evaluation and Analysis of Drug-use in Hospitals of China(中国医院用药评价与分析), 2022, 22(6): 758-760,764.
[16] WANG H, SU W, LOWE S, et al.Association of apatinib and breast cancer: a systematic review and meta-analysis[J]. Surgical Oncology, 2022, 44: 101818.
[17] The Expert Group on Off-label Use of Anlotinib. Expert consensus on off-label use of anlotinib[J]. Chin J Mod Appl Pharm(中国现代应用药学), 2021, 38(24): 3102-3107.
[18] LIM M, SHULMAN DS, ROBERTS H, et al.Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center[J]. Cancer Med, 2020, 9(18): 6658-6666.
[19] FAN QQ, ZHANG B, ZHAO B, et al.215 cases of adverse drug reactions related to small molecule kinase inhibitors. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(5): 550-553,560.
[20] GOZZO L, VETRO C, BRANCATI S, et al.Off-label use of venetoclax in patients with acute myeloid leukemia: single center experience and data from pharmacovigilance database[J]. Front Pharmacol, 2021, 12: 748766.
[21] LIU S, KURZROCK R.Understanding toxicities of targeted agents: implications for anti-tumor activity and management[J]. Semin Oncol, 2015, 42(6): 863-875.
[22] AW DC, TAN EH, CHIN TM, et al.Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities[J]. Asia Pac J Clin Oncol, 2018, 14(1): 23-31.
[23] VERSMISSEN J, COLAFELLA KMM, KOOLEN SLW, et al.Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension[J]. Cardiovasc Res, 2019, 115(5): 904-914.
[24] ZAMORANO JL, LANCELLOTTI P, MUNOZ DR, et al.2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the european society of cardiology (ESC)[J]. Eur Heart J, 2016, 37(36): 2768-2801.